Initial Results from a Pilot Comparative Effectiveness Study of 3 Methotrexate-based Consensus Treatment Plans for Juvenile Localized Scleroderma

Suzanne C. Li, Kathryn S. Torok, C. Egla Rabinovich, Fatma Dedeoglu, Mara L. Becker, Polly J. Ferguson, Sandy D. Hong, Maria F. Ibarra, Katie Stewart, Elena Pope, Gloria C. Higgins, Ronald M. Laxer, Thomas Mason, Robert C. Fuhlbrigge, Tracy Andrews

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Objective. To perform a comparative effectiveness feasibility study in juvenile localized scleroderma (LS), using standardized treatment regimens (consensus treatment plans; CTP). Methods. A prospective, multicenter 1-year pilot observational cohort study was performed by Childhood Arthritis and Rheumatology Research Alliance (CARRA) LS workgroup members. Patients with active, moderate to severe juvenile LS were treated with one of 3 CTP: methotrexate alone, or in combination with intravenous (30 mg/kg/dose for 3 mos) or oral corticosteroids (2 mg/kg/ day tapered by 48 weeks). Results. Fifty patients, with demographics typical for juvenile LS, were enrolled, and 44 (88%) completed the study. Most had extracutaneous involvement. Patients improved in all 3 CTP, with > 75% having a major or moderate level of improvement compared to baseline. Damage accrued in some patients. Major deviations from prescribed regimen resulted from medication intolerance (n = 6; 14%) or treatment failure (n = 11; 25%); failures occurred in all 3 CTP. Significant responses to treatment were demonstrated by LS skin scoring measures and overall physician assessments, with differences in response level identified in some patient subsets. Response differences were associated with baseline disease activity level, LS subtype, skin disease extent, and extracutaneous involvement. Conclusion. This study demonstrates the feasibility of conducting juvenile LS comparative effectiveness studies. The CTP were found to be safe, effective, and tolerable. Our assessments performed well. Because damage is common and may progress despite effective control of activity, we recommend initial treatment efficacy be evaluated primarily by activity measures. Potential confounders for response were identified that warrant further study.

Original languageEnglish (US)
Pages (from-to)1242-1252
Number of pages11
JournalJournal of Rheumatology
Volume47
Issue number8
DOIs
StatePublished - Aug 1 2020
Externally publishedYes

Keywords

  • Clinical trials
  • Disease activity score
  • Methotrexate
  • Pediatric rheumatic diseases
  • Scleroderma

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Initial Results from a Pilot Comparative Effectiveness Study of 3 Methotrexate-based Consensus Treatment Plans for Juvenile Localized Scleroderma'. Together they form a unique fingerprint.

Cite this